FDA clears Scopio Labs hematology analysis platform

By LabPulse.com staff writers

June 10, 2022 -- Medtech firm Scopio Labs announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its X100HT device with peripheral blood smear applications.

Tel Aviv, Israel-based Scopio said the X100HT is a full-field digital imaging and artificial intelligence (AI)-enabled platform that combines high throughput with high resolution for hematological analysis.

With the increasing prevalence of hematological disorders and malignancies, the accuracy and timeliness of peripheral blood smear results are critically important for early diagnosis and effective treatment initiation, the firm noted.

A peripheral blood smear review provides access to information about disorders such as blood related cancers, anemia, infections, and allergies. Most of the tests are performed manually, but Scopio's solution eliminates the need for additional manual microscopic examination.

PixCell signs MakGroup as distributor for the UAE
PixCell Medical has signed MakGroup Healthcare as a new distributor for its HemoScreen point-of-care hematology test in the United Arab Emirates (UAE)....
Scopio completes $50M funding round
Scopio Labs recently completed a $50 million series C funding round that will go toward the company's end-to-end hardware and software platform for...
ASH-ASPHO offers guidance on pediatric hematology tests
Clinical guidelines on hematology testing in pediatric patients were published in Blood Advances on January 24. The guidelines are part of five...
Natera to expand into early cancer detection
Natera plans to expand into the market for early cancer detection to advance the company's strategic growth objectives in the area and has promoted an...

Copyright © 2022 LabPulse.com

Last Updated mp 6/10/2022 7:09:43 AM